Deutsche Bank AG reduced its position in FibroGen Inc (NASDAQ:FGEN) by 49.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 223,364 shares of the biopharmaceutical company’s stock after selling 217,362 shares during the quarter. Deutsche Bank AG’s holdings in FibroGen were worth $10,335,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Meeder Asset Management Inc. increased its stake in FibroGen by 622.4% in the 4th quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 529 shares during the period. Intercontinental Wealth Advisors LLC acquired a new position in FibroGen in the 4th quarter valued at $37,000. Flinton Capital Management LLC acquired a new position in FibroGen in the 4th quarter valued at $44,000. Neuburgh Advisers LLC acquired a new position in FibroGen in the 4th quarter valued at $53,000. Finally, Bank of Montreal Can increased its stake in FibroGen by 177.3% in the 4th quarter. Bank of Montreal Can now owns 1,722 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 1,101 shares during the period. 66.58% of the stock is currently owned by institutional investors.
Several equities analysts have issued reports on the stock. Stifel Nicolaus assumed coverage on shares of FibroGen in a research note on Monday, February 11th. They issued a “buy” rating and a $71.00 price objective on the stock. ValuEngine cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 14th. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 22nd. TheStreet raised shares of FibroGen from a “d+” rating to a “c-” rating in a research note on Friday, March 29th. Finally, Zacks Investment Research cut shares of FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, March 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $71.17.
In other FibroGen news, CEO Thomas B. Neff sold 48,180 shares of the business’s stock in a transaction on Friday, February 8th. The shares were sold at an average price of $56.47, for a total transaction of $2,720,724.60. Following the sale, the chief executive officer now directly owns 2,680,346 shares in the company, valued at approximately $151,359,138.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas B. Neff sold 60,000 shares of the business’s stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $52.00, for a total transaction of $3,120,000.00. Following the sale, the chief executive officer now owns 2,624,016 shares in the company, valued at $136,448,832. The disclosure for this sale can be found here. Insiders have sold a total of 310,321 shares of company stock worth $17,121,964 over the last 90 days. Insiders own 8.96% of the company’s stock.
Shares of NASDAQ FGEN opened at $46.14 on Thursday. The firm has a market cap of $4.17 billion, a price-to-earnings ratio of -44.80 and a beta of 1.72. FibroGen Inc has a one year low of $37.27 and a one year high of $68.55. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.75 and a current ratio of 7.75.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.40. The company had revenue of $108.05 million for the quarter, compared to analyst estimates of $72.15 million. FibroGen had a negative net margin of 40.58% and a negative return on equity of 16.84%. The business’s revenue was up 251.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) EPS. Analysts forecast that FibroGen Inc will post -0.97 EPS for the current year.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Article: Green Investing
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.